[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,298,133
  • Shares Outstanding, K 348,202
  • Annual Sales, $ 62,900 K
  • Annual Income, $ -204,630 K
  • EBIT $ -150 M
  • EBITDA $ -148 M
  • 60-Month Beta 1.52
  • Price/Sales 33.82
  • Price/Cash Flow N/A
  • Price/Book 6.66

Options Overview Details

View History
  • Implied Volatility 111.41% (+22.87%)
  • Historical Volatility 54.95%
  • IV Percentile 75%
  • IV Rank 13.76%
  • IV High 369.46% on 03/27/26
  • IV Low 70.24% on 06/23/26
  • Expected Move (DTE 11) 1.01 (15.44%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 528
  • Volume Avg (30-Day) 784
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 25,284
  • Open Int (30-Day) 24,680
  • Expected Range 5.54 to 7.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 3
  • High Estimate $-0.11
  • Low Estimate $-0.14
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.34 +23.60%
on 07/17/26
6.80 -2.87%
on 07/27/26
+0.79 (+13.60%)
since 07/10/26
3-Month
4.07 +62.16%
on 05/19/26
6.80 -2.87%
on 07/27/26
+1.81 (+37.79%)
since 05/08/26
52-Week
2.18 +202.75%
on 08/11/25
9.75 -32.31%
on 12/22/25
+4.30 (+186.96%)
since 08/08/25

Most Recent Stories

More News
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectinib)

NUVB : 6.60 (unch)
Nuvation Bio's Revenue Stacking Thesis Finally Gets Its First Real Test

Barchart Research What to Expect from NUVB Earnings NUVB Generated August 5, 2026 Current Price $6.37 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 7.80% Nuvation Bio's Revenue Stacking...

NUVB : 6.60 (unch)
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key patient subgroups

NUVB : 6.60 (unch)
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

NEW YORK , July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...

NUVB : 6.60 (unch)
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with   nearly   40   months   of follow-up

NUVB : 6.60 (unch)
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

NEW YORK , July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced...

NUVB : 6.60 (unch)
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK , June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing...

NUVB : 6.60 (unch)
Nuvation Bio Announces Proposed Convertible Senior Notes Offering

NEW YORK , June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today...

NUVB : 6.60 (unch)
Nuvation Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK , May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David...

NUVB : 6.60 (unch)
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

  88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment

NUVB : 6.60 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 7.18
2nd Resistance Point 6.91
1st Resistance Point 6.75
Last Price 6.60
1st Support Level 6.33
2nd Support Level 6.05
3rd Support Level 5.90

See More

52-Week High 9.75
Fibonacci 61.8% 6.86
Last Price 6.60
Fibonacci 50% 5.97
Fibonacci 38.2% 5.07
52-Week Low 2.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.